title: Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.
abstract: <title/> Adult patients with primary immune thrombocytopenia requiring first-line treatment typically receive corticosteroids, which are associated with low response rates and many potential side effects. In a retrospective analysis of two 6-month, placebo-controlled, phase III trials, corticosteroid use decreased from 30 to 26% among patients treated with the novel thrombopoietin-mimetic romiplostim (n = 83) and remained above 30% for placebo-treated patients (n = 42). Moreover, compared to placebo, patients were spared 7 weeks of corticosteroid treatment for every 100 weeks of romiplostim treatment. Thereafter, corticosteroid use continued to decrease significantly, from 35 to 20%, in patients treated with romiplostim for up to 3 years in an open-label extension study (n = 101), and patients were spared a further 8 weeks of corticosteroid treatment for each additional 100 weeks of romiplostim treatment. Such reductions in corticosteroids may improve health-related quality of life in patients with primary immune thrombocytopenia.
authors: CHU Henri Mondor AP-HP, Université Paris, 51 Av du Mal de Lattre de Tassigny, Créteil, France. marc.michel@hmn.aphp.fr
authors: Marc
authors: M
authors: Michel
authors: Peter A W
authors: PA
authors: te Boekhorst
authors: Ann
authors: A
authors: Janssens
authors: Ingrid
authors: I
authors: Pabinger-Fasching
authors: Miguel A
authors: MA
authors: Sanz
authors: Kun
authors: K
authors: Nie
authors: Georg
authors: G
authors: Kreuzbauer
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011961:Receptors, Fc / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000276:immunology; D013926:Thrombopoietin / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000305:Adrenal Cortex Hormones; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim